NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Fibronostics

Fibronostics

Private
New Orleans, LouisianaHealthcare & Life Scienceshttps://fibronostics.com/

Last Round

Series A

Extension

Jun 15, 2022

Total Funding Raised

$14.5M

Company Overview

Fibronostics is a healthcare technology company that provides non-invasive, AI-driven diagnostic solutions for chronic, metabolic, and liver diseases.

Sector

Healthcare & Life Sciences

Verticals

Medical AI, Healthcare Analytics, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

non-invasive diagnosticsliver health diagnosticsAI-powered diagnosticsliver biopsy alternativeNASH testNAFLD testfatty liver diseaseMASLD screeningMASH screeningliquid biopsySoftware as a Medical DeviceSaMDblood biomarker analysismedical AIdigital diagnosticsliver fibrosisclinical trial diagnosticsCPT code

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Fibronostics Comparables

Compare Fibronostics with similar companies based on industry and business-model similarity.

Fibronostics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BioPredictive
85%
MetaDeq
82%
GlycoDiagnostics
77%

Fibronostics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJun 15, 2022
Series AAug 24, 2020
SeedMay 31, 2019

Key People

Founding team and executive leadership

Brock Smith

Chief Executive Officer

Executive Team

Fibronostics Investors

Notable investors and investment history

Fibronostics investors
InvestorRounds
Tikehau CapitalSeries A
AT Capital GroupSeries A
SPRIM Global InvestmentsSeed, Series A
Elev8.vcSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2025

    Monthly visitors grew 33% MoM.

  • May 12, 2025

    Grew 22% QoQ, from 23 to 28 employees.

Fibronostics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Fibronostics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Fibronostics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew Orleans, Louisiana
Employee Range27
Year Founded2015
Last FundingJun 15, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.